Mucoadhesive nanoparticulate system for oral drug delivery: A review

Current Drug Therapy

Volumn 7, Issue 1, 2012, Pages 42-55

  Ahmed, Ayaz ^a   Yadav, Hemant K S ^a   Lakshmi, Sureddi V ^a   Namburi, Bala V N ^a   Shivakumar, Hosakote G ^a  

^a JSS COLLEGE OF PHARMACY   (India)

Author keywords

Microparticles; Mucoadhesion; NPs; Peptide drug; Poorly absorbed drug

Indexed keywords

BUPRAVAQUONE; CARMUSTINE; CHITOSAN; CYCLODEXTRIN; DICOUMAROL; DOXORUBICIN; DOXYCYCLINE HYCLATE; GOSERELIN; INSULIN; IODINATED POPPYSEED OIL; LEUPRORELIN; NANOPARTICLE; OCTREOTIDE; PACLITAXEL; PEPTIDE; POLYMER; POLYSACCHARIDE; TRELSTART; UNCLASSIFIED DRUG; VINCAMINE;

CONTROLLED DRUG RELEASE; CRYPTOSPORIDIUM PARVUM; DIFFUSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG TARGETING; DRUG UPTAKE; EMULSION; ENZYME DEGRADATION; GASTROINTESTINAL TRACT; HUMAN; MUCOADHESION; NONHUMAN; PARTICLE SIZE; PHASE SEPARATION; PRIORITY JOURNAL; REVIEW; SYNTHESIS;

EID: 84860542383     PISSN: 15748855     EISSN: 10657630     Source Type: Journal    
DOI: 10.2174/157488512800389137     Document Type: Review

References (124)

1. Senthilkumar M, Subramanian G, Kumar AR, Manoj N, Pradeep M, Kumar JN. PEGylated Poly (Lactide-co-Glycolide) (PLGA) nanoparticulate delivery of Docetaxel: synthesis of diblock copolymers, optimization of preparation variables on formulation characteristics and in vitro release studies. J Biomed Nanotech 2007; 1: 52-60.
2. Lee VHL, Yamamoto A. Penetration and enzymatic barriers to peptide and protein absorption. Adv Drug Deliv Rev 1990; 4: 171-207.
3. Longer MA, Ch'ng HS, Robinson JR. Bioadhesive polymers as platforms for oral controlled drug delivery III: Oral delivery of chlorothiazide using a bioadhesive polymer. J Pharm Sci 1985; 74: 406-411.
4. Hirofumi T, Hiromitsu Y, Yoshiaki K. Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv Drug Deliv Rev 2001; 47: 39-54.
5. Ponchel G, Irache JM. Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Adv Drug Deliv Rev 1998; 34: 191-219.
6. Jani P, Halbert GW, Langridge J, Florence AT. Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency. J Pharm Pharmacol 1990; 42: 821-826.
7. Jani P, Halbert GW, Langridge J, Florence AT. Uptake and translocation of latex nanospheres and microspheres after oral administration to rats. J Pharm Pharmacol 1989; 41: 809-812.
8. Eldridge JH, Hammond CJ, Meulbroek JA, Staas JK, Gilley RM, Tice TR. Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered bio degradable microspheres target the Payer's patches. J Control Release 1990; 11: 205-214.
9. Ponchel G, Montisci MJ, Dembri A, Durrer C, Duchene D. Mucoadhesion of colloidal particulate systems in the gastrointestinal tract. Eur J Pharm Biopharm 1997; 44: 25-31.
10. Kayser O. A new approach for targeting to Cryptosporidium parvum using mucoadhesive nanosuspensions: research and applications. Int J Pharm 2001; 214: 83-85.
11. Allemann E, Leroux JC, Gurny R. Polymeric nanoparticles and microparticles for the oral delivery of peptides and peptidomimetics. Adv Drug Deliv Rev 1998; 34: 171-189.
12. Arbos P, Campanero MA, Arangoa MA, Renedo MJ, Irache JM. Influence of the surface characteristics of PVM/MA nanoparticles on their bioadhesive properties. J Control Release 2003; 89: 19-30.
13. Volkheimer G, Schulz FH. The phenomenon of persorption. Digestion 1968; 1: 213-218.
14. Florence AT. The oral absorption of micro and nanoparticulates: neither exceptional nor unusual. Pharm Res 1997; 14(3): 259-266.
15. Hans ML, Lowman AM. Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater Sci 2002; 6: 319-327.
16. Knowles MR, Boucher RC. Mucus clearance as a primary innate defence mechanism for mammalian airways. J Clin Invest 2002; 109: 571-577.
17. Cone R. Mucus. In: Michael WS, Lamm E, McGhee JR, Mayer L, Mestecky J, Bienenstock J (Eds.). Mucosal Immunology, Academic Press, San Diego. 1999; 43-64.
18. Cone R. Barrier properties of mucus. Adv Drug Deliv Rev 2009; 61: 75-85.
19. Teng CLC. Kinetics of adhesion of polymer-coated particles to intestinal mucous surface. PhD Thesis, The University of Michigan, U.M.I. Dissertation Services, Order number 8712222, Ann Arbor, 1987.
20. Teng CLC, Ho NFH. Mechanistic studies in the simultaneous flow and adsorption of polymer-coated latex particles on intestinal mucus: I. Methods and physical model development. J Control Release 1987; 6: 133-149.
21. Leo E, Angela VM, Cameroni R, Forni F. Doxorubicin-loaded gelatin nanoparticles stabilized by glutaraldehyde: involvement of the drug in the cross-linking process. Int J Pharm 1997; 155: 75-82.
22. Lehr CM. From sticky stuff to sweet receptors-achievements, limits, and novel approaches to bioadhesion. Eur J Drug Metab Pharmacokin 1996; 21: 139-148.
23. Gabor F, Bogner E, Weissenboeck A, Wirth M. The lectin-cell interaction and its implications to intestinal lectin-mediated drug delivery. Adv Drug Deliv Rev 2004; 56: 459-480.
24. Chen H, Langer R. Oral particulate delivery: status and future trends. Adv Drug Deliv Rev 1998; 34: 339-350.
25. Yeh P, Ellens H, Smith PL. Physiological considerations in the design of particulate dosage forms for oral vaccine delivery. Adv Drug Deliv Rev 1998; 34: 123-133.
26. LeFevre ME, Warren JB, Joel DD. Particles and macrophages in murine Peyer's patches. Exp Cell Biol 1985; 53: 121-9.
27. Hussain N, Jaitley V, Florence AT. Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. Adv Drug Deliv Rev 2001; 50: 107-42.
28. Lehr CM. Lectin-mediated drug delivery: the second generation of bioadhesives. J Control Release 2000; 65: 19-29.
29. Lemarchand C, Gref R, Couvreur P. Polysaccharide-decorated nanoparticles. Eur J Pharm Biopharm 2004; 58: 327-341.
30. Borchard G, Lueben HL, de Boer AG, Verhoef JC, Lehr CM, Junginger HE. The potential of mucoadhesive polymers in enhancing intestinal peptide drug absorption. III: effects of chitosan-glutamate and carbomer on epithelial tight junctions in vitro. J Control Release 1996; 39: 131-138.
31. Duchene D, Ponchel G. Bioadhesion of solid oral dosage forms, why and how? Eur J Pharm Biopharm 1997; 44: 15-23.
32. Jaeghere FD, Doelker E, Gurny R. Encyclopedia of controlled drug delivery. In: Mathiowitz E, ed. Nanoparticles. New York: John Wiley & Sons, 1999; 641-663.
33. Pappo J. Generation and characterization of monoclonal antibodies recognizing follicle epithelial M cells in rabbit gut associated lymphoid tissues. Cell Immunol 1989; 120: 31-41.
34. Rodrigues JS, Santos-Magalhaes NS, Coelho LCBB, Couvreur P, Ponchel G, Gref R. Novel core(polyester)-shell(polysaccharide) nanoparticles: protein loading and surface modification with lectins. J Control Release 2003; 92: 103-112.
35. Florence AT, Hillery AM, Hussain N, Jani PU. Nanoparticles as carriers for oral peptide absorption: studies on particle uptake and fate. J Control Release 1995; 36: 39-46.
36. Weissenbock A, Wirth M, Gabor F. WGA-grafted PLGA-nanospheres: preparation and association with Caco-2 single cells. J Control Release 2004; 99: 383-392.
37. Arangoa MA, Ponchel G, Orecchioni AM, Renedo MJ, Duchene D, Irache JM. Bioadhesive potential of gliadin nanoparticulate systems. Eur J Pharm Sci 2000; 11: 333-341.
38. Dekker J, Rossen JWA, Buller HA, Einerhand AWC. The MUC family: an obituary. Trends Biochem Sci 2002; 27: 126-131.
39. Mainardes RM, Urban MC, Cinto PO, Chaud MV, Evangelista RC, Gremiao MP. Liposomes and micro/nanoparticles as colloidal carriers for nasal drug delivery. Curr Drug Deliv 2006; 3: 275-285.
40. Saketkhoo K, Januszkiewicz A, Sackner MA. Effects of drinking hot water, cold water, and chicken soup on nasal mucus velocity and nasal airflow resistance. Chest 1978; 74: 408-410.
41. Ali MS, Pearson JP. Upper airway mucin gene expression: a review. Laryngoscope 2007; 117: 932-938.
42. Jayaraman S, Joo NS, Reitz B, Wine JJ, Verkman AS. Submucosal gland secretions in airways from cystic fibrosis patients have normal [Na(+)] and pH but elevated viscosity. Proc Natl Acad Sci USA. 2001; 98: 8119-8123.
43. Greaves JL, Wilson CG. Treatment of diseases of the eye with Mucoadhesive delivery systems. Adv Drug Deliv Rev 1993; 11: 349-383.
44. Schreiber S, Scheid P. Gastric mucus of the guinea pig: proton carrier and diffusion barrier. Am J Physiol 1997; 272: 63-70.
45. Boskey ER, Cone RA, Whaley KJ, Moench TR. Origins of vaginal acidity: high D/L lactate ratio is consistent with bacteria being the primary source. Hum Reprod 2001; 16: 1809-1813.
46. Galindo-Rodriguez SA, Allemann E, Fessi H, Doelker E. Polymeric nanoparticles for oral delivery of drugs and vaccines: a critical evaluation of in vivo studies. Crit Rev Ther Drug Carr Syst 2005; 22: 419-464.
47. Lehr CM, Poelma FGJ, Junginger HE, Tukker JJ. An estimate of turnover time of intestinal mucus gel layer in the rat in situ loop. Int J Pharm 1991; 70: 235-240.
48. Kieweg SL, Geonnotti AR, Katz DF. Gravity-induced coating flows of vaginal gel formulations: in vitro experimental analysis. J Pharm Sci 2004; 93: 2941-2952.
49. Kieweg SL, Katz DF. Squeezing flows of vaginal gel formulations relevant to microbicide drug delivery. J Biomech Eng 2006; 128: 540-553.
50. Clunes MT, Boucher RC. Cystic fibrosis: the mechanisms of pathogenesis of an inherited lung disorder. Drug Discov Today Dis Mech 2007; 4: 63-72.
51. Matsui H, Grubb BR, Tarran R, et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998; 95: 1005-1015.
52. Tarran R, Grubb BR, Gatzy JT, Davis CW, Boucher RC. The relative roles of passive surface forces and active ion transport in the modulation of airway surface liquid volume and composition. J Gen Physiol 2001; 118: 223-236.
53. Verkman AS, Song Y, Thiagarajah JR. Role of airway surface liquid and submucosal glands in cystic fibrosis lung disease. Am J Physiol Cell Physiol 2003; 284: C2-C15.
54. Behrens I, Stenberg P, Artursson P, Kissel T. Transport of lipophilic drug molecules in a new mucus-secreting cell culture model based on HT29-MTX cells. Pharm Res 2001; 18: 1138-1145.
55. Copeman M, Matuz J, Leonard AJ, Pearson JP, Dettmar PW, Allen A. The gastroduodenal mucus barrier and its role in protection against luminal pepsins: the effect of 16,16-dimethyl prostaglandin E2, carbopol-polyacrylate, sucralfate and bismuth subsalicylate. J Gastroenterol Hepatol 1994; 9 (Suppl 1): S55-S59.
56. Matsuo K, Ota H, Akamatsu T, Sugiyama A, Katsuyama T. Histochemistry of the surface mucous gel layer of the human colon. Gut 1997; 40: 782-789.
57. Pullan RD, Thomas GA, Rhodes M, et al. Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis. Gut 1994; 35: 353-359.
58. Van der Waaij LA, Harmsen HJ, Madjipour M, et al. Bacterial population analysis of human colon and terminal ileum biopsies with 16S rRNA-based fluorescent probes: commensal bacteria live in suspension and have no direct contact with epithelial cells. Inflamm Bowel Dis 2005; 11: 865-871.
59. Jordan N, Newton J, Pearson J, Allen A. A novel method for the visualization of the in situ mucus layer in rat and man. Clin Sci (Lond) 1998; 95: 97-106.
60. Kerss S, Allen A, Garner A. A simple method for measuring thickness of the mucus gel layer adherent to rat, frog and human gastric mucosa: influence of feeding, prostaglandin, N-acetylcysteine and other agents. Clin Sci (Lond) 1982; 63: 187-195.
61. Holly FJ, Lemp MA. Tear physiology and dry eyes. Surv Ophthalmol 1977; 22: 69-87.
62. King-Smith PE, Fink BA, Hill RM, Koelling KW, Tiffany JM. The thickness of the tear film. Curr Eye Res 2004; 29: 357-368.
63. Prydal JI, Artal P, Woon H, Campbell FW. Study of human precorneal tear film thickness and structure using laser interferometry. Invest Ophthalmol Vis Sci 1992; 33: 2006-2011.
64. Chickering D, Jacob J, Mathiowitz E. Poly (fumaric-co-sebacic) microspheres as oral drug delivery systems. Biotechnol Bioeng 1996; 52: 96-101.
65. Mathiowitz E, Jacob JS, Jong YS, et al. Biologically erodable microsphere as potential oral drug delivery system. Nature 1997; 386: 410-414.
66. Bernkop-Schnurch A. Thiomers: a new generation of mucoadhesive polymers. Adv Drug Deliv Rev 2005; 57: 1569-1582.
67. Prego C, Torres D, Alonso MJ. The potential of chitosan for the oral administration of peptides. Expert Opin Drug Deliv 2005; 2: 843-854.
68. Janes KA, Calvo P, Alonso MJ. Polysaccharide colloidal particles as delivery systems for macromolecules. Adv Drug Deliv Rev 2001; 47: 83-97.
69. Fernandez-Urrusuno R, Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm Res 1999; 16: 1576-1581.
70. Pan Y, Li YJ, Zhao HY, et al. Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int J Pharm 2002; 249: 139-147.
71. Prego C, Torres D, Alonso MJ. Chitosan nanocapsules as carriers for oral peptide delivery: effect of chitosan molecular weight and type of salt on the in vitro behavior and in vivo effectiveness. J Nanosci Nanotechnol 2006; 6: 2921-2928.
72. Roy K, Mao HQ, Huang SK, Leong KW. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med 1999; 5: 387-391.
73. Damgé C, Vranckx H, Balschmidt P, Couvreur P. Poly(alkyl cyanoacrylate) nanospheres for oral administration of insulin. J Pharm Sci 1997; 86: 1403-1409.
74. Lowe PJ, Temple CS. Calcitonin and insulin in isobutylcyanoacrylate nanocapsules: protection against proteases and effect on intestinal absorption in rats. J Pharm Pharmacol 1994; 46: 547-552.
75. Sarmento B, Ribeiro A, Veiga F, Sampaio P, Neufeld R, Ferreira D. Alginate/ chitosan nanoparticles are effective for oral insulin delivery. Pharm Res 2007; 24: 2198-2206.
76. Atuma C, Strugala V, Allen A, Holm L. The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo, Am J Physiol: Gasterointest Liver Physiol 2001; 280: G922-G929.
77. Strugala V, Allen A, Dettmar PW, Pearson JP. Colonic mucin: methods of measuring mucus thickness. Proc Nutr Soc 2003; 62: 237-243.
78. Szentkuti L, Lorenz K. The thickness of the mucus layer in different segments of the rat intestine. Histochem J 1995; 27: 466-472.
79. Maincent P, LeVerge R, Sado P, Couvreur P, Devissaguet JP. Deposition kinetics and oral bioavailability of vincamine-loaded polyalkyl cyanoacrylate nanoparticles. J Pharm Sci 1986; 75: 955-958.
80. Damgé C, Aprahamian M, Balboni G, Hoeltzel A, Andrieu V, Devissaguet JP. Polyalkylcyanoacrylate nanocapsules increase the intestinal absorption of a lipophilic drug. Int J Pharm 1987; 36: 121-125.
81. Ammoury N, Fessi H, Devissaguet JP, Dubrasquet M, Benita S. Jejunal absorption, pharmacological activity, and pharmacokinetic evaluation of indomethacin-loaded poly(D,L-lactide) and poly(isobutyl-cyanoacrylate) nanocapsules in rats. Pharm Res 1991; 8: 101-105.
82. Damgé C, Michel C, Aprahamian M, Couvreur P, Devissaguet JP. Nanocapsules as carriers for oral peptide delivery. J Control Release 1990; 13: 233-239.
83. Damgé C, Michel C, Aprahamian M, Couvreur P. New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier. Diabetes 1988; 37: 246-251.
84. Marriott C, Gregory NP: Mucus physiology and pathology in Bioadhesive Drug Delivery Systems, Eds. V. Lenaerts, R. Gurny, CRC Press, Inc Florida 1990; 1.
85. Yang X, Robinson JR. Bioadhesion in Mucosal Drug Delivery in Biorelated Polymers and Gels. Ed. T. Okano, Academic Press, US.A. 1998; 135-192.
86. Bansil R, Stanley E, LaMont JT. Mucin biophysics. Annu Rev Physiol 1995; 57: 635-657.
87. Lehr CM, Poelma FGJ, Junginger HE, Tukker JJ. An estimate of turnover time of intestinal mucus gel layer in the rat in situ loop. Int J Pharm 1991; 70: 235-240.
88. Jung T, Kamm W, Breitenbach A, Kaiserling E, Xiao JX, Kissel T. Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? Eur J Pharm Biopharm 2000; 50: 147-160.
89. Delie F. Evaluation of nano- and microparticle uptake by the gastrointestinal tract. Adv Drug Del Rev 1998; 34: 221-233.
90. Artursson P, Lindmark T, Davis SS, Illum L. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm Res 1994; 11: 1358-1361.
91. Thanou M, Verhoef JC, Junginger HE. Oral drug absorption enhancement by chitosan and its derivatives. Adv Drug Deliv Rev 2001; 52: 117-126.
92. Pan Y, Li Y, Zhao H, et al. Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int J Pharm 2002; 249: 139-147.
93. van der Lubben IM, Verhoef JC, Borchard G, Junginger HE. Chitosan for mucosal vaccination. Adv Drug Deliv Rev 2001; 52: 139-144.
94. Duchene D, Ponchel G, Wouessidjewe D. Cyclodextrins in targeting: application to nanoparticles. Adv Drug Deliv Rev 1999; 36: 29-40.
95. Boudad H, Legrand P, Lebas G, Cheron M, Duchene D, Ponchel G. Combined hydroxypropyl-[beta]-cyclodextrin and poly (alkylcyanoacrylate) nanoparticles intended for oral administration of saquinavir. Int J Pharm 2001; 218: 113-124.
96. Arbos P, Campanero MA, Arangoa MA, Irache JM. Nanoparticles with specific bioadhesive properties to circumvent the presystemic degradation of fluorinated pyrimidines. J Control Release 2004; 96: 55-65.
97. Jacobs C, Kayser O, Muller RH. Production and characterization of mucoadhesive nanosuspensions for the formulation of bupravaquone. Int J Pharm 2001; 214: 3-7.
98. Jacobs C, Kayser O, Waters WR, Keithly JS. Anticryptosporidial activity of bupravaquone and improving its in vivo efficacy by the formulation as a mucoadhesive nanosuspension. Proceedings of the International Symposium on Controlled Release of Bioactive Materials, Paris 2000; 7-13 July.
99. Kayser O. A new approach for targeting to Cryptosporidium parvum using mucoadhesive nanosuspensions: research and applications. Int J Pharm 2001; 214: 83-85.
100. Kreuter J. Nanoparticles. In: J. Kreuter (Ed.). Colloidal Drug Delivery Systems. Marcel Dekker Inc, New York, 1994; pp. 219-342.
101. Kawashima Y. New processes - application of spherical crystallization to particulate design of pharmaceuticals for direct tabletting and coating, and new drug delivery system. In: Chulia D, Deleuil M, Pourcelot Y (Eds.), Handbook of Powder Technology, Vol. 9, Elsevier, Amsterdam, 1994; pp. 493-512.
102. Niwa T, Takeuchi H, Hino T, Kunou N, Kawashima Y. Preparations of biodegradable nanospheres of watersoluble and insoluble drugs with DL-lactide/glycolide copolymer by a novel spontaneous emulsification solvent diffusion method, and the drug release behavior. J Control Release 1993; 25: 89-98.
103. Niwa T, Takeuchi H, Hino T, Nohara M, Kawashima Y. Biodegradable submicron carriers for peptide drugs: Preparation of DL-lactide/glycolide copolymer (PLGA) nanospheres with nafarelin acetate by a novel emulsion-phase separation method in an oil system. Int J Pharm 1995; 121: 45-54.
104. Kawashima Y, Yamamoto H, Takeuchi H, Hino T, Niwa H. Properties of a peptide containing DL-lactide/glycolide copolymer nanospheres prepared by novel emulsion solvent diffusion methods. Eur J Pharm Biopharm 1998; 45: 41-48.
105. Takeuchi H, Yamamoto H, Kawashima Y. Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv Drug Deliv Rev 2001; 47: 39-54.
106. Sunamoto J, Iwamoto K, Takada M, Yuzuriha T, Katayama K. Improved drug delivery to target specific organs using liposomes as coated with polysaccharides. Polymer Sci Technol 1983; 23: 157-168.
107. Sunamoto J, Iwamoto K, Takada M, Yuzuriha T, Katayama K. Polymer coated liposomes for drug delivery to target specific organs. In: Anderson JM, Kim SW (Eds.), Recent Advances in Drug Delivery Systems, 1984, pp. 153-162.
108. Jamshaid M, Farr SJ, Kearney P, Kellaway IW. Poloxamer sorption on liposomes: comparison with polystyrene latex and influence on solute efflux. Int J Pharm 1988; 48: 125-131.
109. Kronberg B, Dahlman A, Carlfors J, Karlsson J, Artursson P. Preparation and evaluation of sterically stabilized liposomes: colloidal stability, serum stability, macrophage uptake, and toxicity. J Pharm Sci 1990; 79: 667-671.
110. Dong C, Rogers JA. Polymer-coated liposomes: stability and release of ASA from carboxymethyl chitin-coated liposomes. J Control Release 1991; 17: 217-224.
111. Alamelu S, Rao KP. Studies on the carboxymethyl chitosan-containing liposomes for their stability and controlled release of dapson. J Microencapsul 1991; 8: 505-515.
112. Elferink WGL, de Wit JG, In't Veld G, et al. The stability and functional properties of proteoliposomes mixed with dextran derivatives bearing hydrophobic anchor groups. Biochim Biophys. Acta 1992; 1106: 23-30.
113. Peppas NA, Mikos AG. Experimental methods for determination of bioadhesive bond strength of polymers with mucus. Stp Pharma 1989; 5: 187-191. STP Sci Techn Prat
114. Ranga Rao KV, Buri PA. Novel in situ method to test polymers and coated microparticles for bioadhesion. Int J Pharm 1989; 52: 265-270.
115. Lehr CM, Bouwstra JA, Tukker JJ, Junginger HE. Intestinal transit of bioadhesive microspheres in an in situ loop in the rat-a comparative study with copolymers and blends based on poly (acrylic acid). J Control Release 1990; 13: 51-62.
116. Durrer C, Irache JM, Puisieux F, Duchene D, Ponchel G. Mucoadhesion of latexes: I. Analytical methods and kinetic studies. Pharm Res 1994; 11: 674-679.
117. Durrer C, Irache JM, Puisieux F, Duchene D, Ponchel G. Mucoadhesion of latexes: II. Adsorption isotherms and desorption studies. Pharm Res 1994; 11: 680-683.
118. Kreuter J, Muller U, Munz K. Quantitative and micro-autoradiographic study on mouse intestinal distribution of polycyanoacrylate nanoparticles. Int J Pharm 1989; 55: 39-45.
119. Pimienta C, Chouinard F, Labib A, Lenaerts V. Effect of various poloxamer coatings on in vitro adhesion of isohexylcyanoacrylate nanospheres to rat ileal segments under liquid flow. Int J Pharm 1992; 80: 1-8.
120. Kawashima Y, Yamamoto H, Takeuchi H, Kuno Y. Mucoadhesive DL-lactide/glycolide copolymer nanospheres coated with chitosan to improve oral delivery of elcatonin. Pharm Dev Technol 2000; 5: 77-85.
121. National Cancer Institute, NCI Alliance for Nanotechnology in Cancer [Homepage on the Internet]. Available from: http://nano.cancer.gov/learn/now/
122. Wagner V, Dullaart A, Bock AK, Zweck A. The emerging nanomedicine landscape. Nat Biotech 2006; 24: 1211-1217.
123. Farokhzad OC, Langer R. Nanomedicine: Developing smarter therapeutic and diagnostic modalities. Adv Drug Deliv Rev 2006; 58: 1456-1459.
124. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003; 348: 2491-2499.